Adenoviral Conjunctivitis

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

AlconFORT WORTH, TX

1 program

AL-46383A Ophthalmic SolutionPhase 21 trial

Active Trials

NCT00901693Terminated452Est. Jul 2010

IVIEW TherapeuticsNJ - Cranbury

1 program

IVIEW-1201Phase 21 trial

Active Trials

NCT03749317Completed135Est. Dec 2024

NicOxFrance - Biot

1 program

Iota-CarrageenanPhase 21 trial

Active Trials

NCT03009799Withdrawn0Est. Sep 2017

OkogenTX - Plano

1 program

OKG-0301Phase 21 trial

Active Trials

NCT03856645Unknown219Est. Jun 2022

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

IVIEW TherapeuticsIVIEW-1201

OkogenOKG-0301

NicOxIota-Carrageenan

AlconAL-46383A Ophthalmic Solution

Clinical Trials (4)

Total enrollment: 806 patients across 4 trials

NCT03749317 IVIEW TherapeuticsIVIEW-1201

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis

Start: Feb 2023Est. completion: Dec 2024135 patients

Phase 2Completed

NCT03856645 OkogenOKG-0301

OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis

Start: Feb 2019Est. completion: Jun 2022219 patients

Phase 2Unknown

NCT03009799 NicOxIota-Carrageenan

Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)

Start: Jan 2017Est. completion: Sep 20170

Phase 2Withdrawn

NCT00901693 AlconAL-46383A Ophthalmic Solution

An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis

Start: Jun 2009Est. completion: Jul 2010452 patients

Phase 2Terminated

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.